Le Lézard
Classified in: Oil industry, Business
Subject: ERN

In 9M19, Braskem generated free cash flow of R$2.8 billion


SÃO PAULO, Nov. 14, 2019 /PRNewswire/ -- BRASKEM S.A. (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK) announces today its results for 3Q19.

HIGHLIGHTS:

Braskem - Consolidated:

Brazil:

United States and Europe:

Mexico:

The full earnings release is available on the Company's IR website: http://www.braskem-ri.com.br/home-en

Braskem will host conference calls to discuss its Results MONDAY, November 18, at 11:00 a.m. US ET.

Additional information may be obtained from the Investor Relations Department at +55 11 3576-9531 or braskem-ri@braskem.com.br

SOURCE Braskem S.A.


These press releases may also interest you

at 03:30
Decathlon, a pioneer in applying RFID technology, has taken an early lead among global retailers in adopting intelligent automation solutions Geek+ systems have been deployed in seven phases on Decathlon sites, with two new sites set up remotely at...

at 03:05
transcosmos inc. has opened a new business location in Kuala Lumpur, the second branch office of TRANSCOSMOS (MALAYSIA) SDN BHD (Headquarters: Kuala Lumpur, Malaysia; transcosmos Malaysia), a company established in 2014, in order to accommodate the...

at 03:00
Billhighway, the leading financial management platform serving component-based organizations, is proud to announce the launch of a new integration with ePly, an innovative conference management software company. The collaborative solution provides...

at 03:00
Swiss Post Solutions (SPS), a leading outsourcing provider for business process solutions and innovative services in document management, announced today that it is partnering with Lehigh University to provide campus mail services. Located in...

at 03:00
HashCash Consultants is extending its blockchain expertise through scalable solutions and services specifically designed to bring reformation within the real estate sector. The USA based company's blockchain solutions for real estate aims to address...

at 02:47
Lipidor AB today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to commence in Q1 2021...



News published on 14 november 2019 at 21:45 and distributed by: